Back to Search Start Over

Novel and Founder Pathogenic Variants in X-Linked Alport Syndrome Families in Greece.

Authors :
Hadjipanagi, Despina
Papagregoriou, Gregory
Koutsofti, Constantina
Polydorou, Christiana
Alivanis, Polichronis
Andrikos, Aimilios
Christodoulidou, Stalo
Dardamanis, Manthos
Diamantopoulos, Athanasios A.
Fountoglou, Anastasios
Frangou, Eleni
Georgaki, Eleni
Giannikouris, Ioannis
Gkinis, Velissarios
Goudas, Pavlos C.
Kalaitzidis, Rigas G.
Kaperonis, Nikolaos
Koutroumpas, Georgios
Makrydimas, George
Myserlis, Grigorios
Source :
Genes; Dec2022, Vol. 13 Issue 12, p2203, 22p
Publication Year :
2022

Abstract

Alport syndrome (AS) is the most frequent monogenic inherited glomerulopathy and is also genetically and clinically heterogeneous. It is caused by semi-dominant pathogenic variants in the X-linked COL4A5 (NM_000495.5) gene or recessive variants in the COL4A3/COL4A4 (NM_000091.4/NM_000092.4) genes. The disease manifests in early childhood with persistent microhematuria and can progress to proteinuria and kidney failure in adolescence or early adulthood if left untreated. On biopsy, pathognomonic features include alternate thinning, thickening and lamellation of the glomerular basement membrane (GBM), in the presence of podocyte foot process effacement. Although previous studies indicate a prevalence of AS of about 1/50,000, a recent publication reported a predicted rate of pathogenic COL4A5 variants of 1/2320. We herewith present 98 patients (40 M/58 F) from 26 Greek families. We are selectively presenting the families segregating the X-linked form of AS with pathogenic variants in the COL4A5 gene. We found 21 different pathogenic variants, 12 novel: eight glycine and one proline substitutions in the collagenous domain, one cysteine substitution in the NC1 domain, two premature termination of translation codons, three splicing variants, one 5-bp insertion/frameshift variant, one indel-frameshift variant and four gross deletions. Notably, patients in six families we describe here and three families we reported previously, carried the COL4A5-p.G624D substitution, a founder defect encountered all over Europe which is hypomorphic with mostly milder symptomatology. Importantly, on several occasions, the correct genetic diagnosis reclassified patients as patients with AS, leading to termination of previous immunosuppressive/cyclosporine A therapy and a switch to angiotensin converting enzyme inhibitors (ACEi). With the understanding that all 98 patients span a wide range of ages from infancy to late adulthood, 15 patients (11 M/4 F) reached kidney failure and 11 (10 M/1 F) received a transplant. The prospects of avoiding lengthy diagnostic investigations and erroneous medications, and the advantage of delaying kidney failure with very early administration of renin-angiotensin-aldosterone system (RAAS) blockade, highlights the importance of timely documentation of AS by genetic diagnosis. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20734425
Volume :
13
Issue :
12
Database :
Complementary Index
Journal :
Genes
Publication Type :
Academic Journal
Accession number :
160986382
Full Text :
https://doi.org/10.3390/genes13122203